83
BIBLIOGRAFIA
aan het Rot M, Mathew SJ, Charney DS Neurobiological mechanisms in
major depressive disorder. CMAJ 2009; 180:305-13.
American Psychiatric Association Diagnostic and statistical manual of mental
disorders (DSM-IV). Washington DC, 1994.
American Psychiatric Association, Task force on electroconvulsive therapy,
The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging, Washington, APA Press, 1990.
Andersen K, Lolk A, Kragh-Sorensen P, Peterson NE, Green A Depression
and the risk of Alzheimer disease . Epidemiology 2005; 16:233-38.
Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R,
Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Offord D, Ustun TB, Wittchen HU.The epidemiology of major
depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003;12:3-21.
Antunes PB, Rosa MA, Belmonte -de-Abreu PS, Lobato MI, Fleck MP.
Electroconvulsive therapy in major depression: current aspects. Rev Bras
Psiquiatr 2009; 31:S26-33.
Arancibia S, Silhol M, Moulière F, Meffre J, Hollinger I, Maurice T, Tapia-Arancibia L Protective effect of BDNF against beta-amyloid induced
neurotoxicity in vitro and in vivo in rats. Neurobiol Disease 2008; 31:316-326.
Arancio O and Chao MV Neurotrophins, synaptic plasticity and dementia. Curr Op Neurobiol 2007; 17:325-330.
Arispe N., Pollard H.B., Rojas E. Giant multilevel cation channels formed by
Alzheimer disease amyloid β-protein [AβP-(1–40)] in bilayer membranes.
Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(22):10573–10577.
Arvanitis DN, Ducatenzeiler A, Ou JN, Grodstein E, Andrews SD, Tendulkar SR, Ribeiro-da-Silva A, Szyf M, Cuello AC High intracellular concentrations
84
of amyloid-beta block nuclear translocation of phosphorylated CREB. J
Neurochem 2007; 103(1):216–228.
Aznar S, Knudsen GM Depression and Alzheimer's disease: is stress the
initiating factor in a common neuropathological cascade? J Alzheimers Dis
2011; 23:177-93.
Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia. 2005; 46:8-13.
Bezprozvanny I, Hayden MR Deranged neuronal calcium signaling and
Huntington disease. Biochemical and Biophysical Research Communications. 2004; 322:1310-1317.
Biessels GJ, Staekenborg S, Brunner E., Brayne C, Scheltens P. Risk of
dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;
5:64-74.
Birns J, Kalra L Cognitive function and hypertension. J Hum Hypertens. 2009;23:86-96.
Blake AD, Badway AC, Strowski MZ Delineating somatostatin's neuronal
actions. Curr Drug Targets CNS Neurol Disord 2004; 3:153–160.
Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, Jellinger K, Tragl KH, Fischer P Plasma amyloid beta-42 independently
predicts both late-onset depression and Alzheimer disease. Am J Geriatr
Psychiatry. 2010;18:973-82.
Bocchio-Chiavetto L, Zanardini R, Bortolomasi M et al. Electroconvulsive
therapy (ECT) increases serum brainderived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur. Neuropsychopharmacol. 2006;
16:620-24.
Bora E, Vahip S, Akdeniz F et al. The effect of previous psychotic mood
episodes on cognitive impairment in euthymic bipolar patients. Bipolar Disord
2007; 9:468-77.
Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D et al. Familial Alzheimer’s
85
diseaselinked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17:1005-1013.
Bramham CR, Messaoudi E BDNF function in adult synaptic plasticity: the
synaptic consolidation hypothesis. Prog Neurobiol 76: 99-125. 2005.
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC.Cross-national epidemiology of
DSM-IV major depressive episode. BMC Med. 2011 26; 9:90.
Bulbena A, Berrios GE.Cognitive function in the affective disorders: a
prospective study. Psychopathology. 1993; 26:6-12.
Bunney WE Jr & Davis JM Norepinephrine in depressive reactions. A
review. Arch. Gen. Psychiatry 1965 13: 483–494.
Charney DS, Manji HK Life stress, genes, and depression: multiple pathways
lead to increased riskand new opportunities for intervention. Sci STKE 2004;
re5.
Chen YW, Dilsaver SC Lifetime rates of suicide attempts among subjects
with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry. 1996.
Choi DW. Excitotoxic cell death. Journal of Neurobiology. 1992;23: 1261– 1276.
Christensen R, Marcussen AB, Wortwein G, Knudsen GM, Aznar S Abeta
(1-42) injection causes memory impairment, lowered corticaland serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Exp Neurol 2008;
210:164-71.
Cleve Clin , Depression: a shared risk factor for cardiovascular and
Alzheimer disease. J.med.2011; 78:44-6.
Colaianna M, Tucci P, Zotti M, Morgese MG, Schiavone S, Govoni S, Cuomo V, Trabace L Soluble beta amyloid(1-42): a critical player in producing
behavioural and biochemical changes evoking depressive-related state? Br J
86
Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M Brain-derived
neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain
Res 1997; 49:71–81.
Conti L e coll., Terapia elettroconvulsivante, in Trattato italiano di psichiatria, a cura di P. Pancheri, G.B. Cassano, Milano, Masson, 1999, 2451-72.
Coryell W, Solomon D, Turvey C, et al. The long-term course of rapid-cycling
bipolar disorder. Arch Gen Psychiatry. 2003; 60:914–920.
Coyle JT & Duman RS Finding the intracellular signaling pathways affected
by mood disorder treatments. Neuron 2003; 38:157–160.
Crews L, Masliah E Molecular mechanisms of neurodegeneration in
Alzheimer's disease. Hum Mol Genet. 2010; 19:R12–20.
Crouch PJ, Harding SM, White AR, Camakaris J, Bush AI, et al. Mechanisms
of A beta mediated neurodegeneration in Alzheimer's disease. Int J Biochem
Cell Biol. 2008; 40:181–198.
Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer
disease: challenges to early intervention. Neurology. 2007; 69:1622–1634.
Daly JJ, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Roose SP, Sackeim HA ECT in bipolarand unipolar depression: differences in speed
of response. Bipolar Disorders 2001; 3:95-104.
Davies CA, Mann DMA, Sumpter PQ, Yates PO. A quantitative morphometric
analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease. Journal of the Neurological
Sciences. 1987;78:151–164.
Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B RAGE mediates amyloid-beta peptide transport
across the blood-brain barrier and accumulation in brain. Nat Med 2003;
87
Deane R, Wu Z, Zlokovic BV RAGE (yin) versus LRP (yang) balance
regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004; 35:2628–31.
Deane R, Bell RD, Sagare A, Zlokovic BV Clearance of amyloid-beta peptide
across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8:16-30.
Dell’Osso L, Del Debbio A, Veltri A, Bianchi C, Roncaglia I, Carlini M, Massimetti G, Catena Dell’Osso M, Vizzaccaro C, Marazziti D, Piccinni A
Associations between Brain-Derived Neurotrophic Factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients.
Neuropsychobiology 2010; 62(4):207-212.
Dell’Osso L, Bianchi C, Del Debbio A, Roncaglia I, Veltri A, Carlini M, Catena Dell’Osso M, Origlia N, Domenici L, Marazziti D, Piccinni A. Plasma
brain-derived neurotrophic factor in bipolar and unipolar depression. Giorn Ital
Psicopat 2010; 16:138-143.
Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium
dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. Journal of Biological Chemistry.
2005; 280:17294-17300.
Devanand DP, Fitzsimons L, Prudic J, Sackeim HA . Subjective side effects
during electroconvulsive therapy. Convuls Ther. 1995 ; 11(4):232-40.
Di Sciascio G, Calò S La terapia elettroconvulsivante del trattamento della
depressione maggiore resistente. Quaderni Italiani di Psichiatria 2010;
29(4):140-145.
Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P.
Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995; 16:285-298.
Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG.
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta
88
Dotson VM, Beydoun MA, Zonderman AB Recurrent depressive symptoms
and the incidence of dementia and mild cognitive impairment. Neurology
2010; 75:27–34.
Dubovski, Electroconvulsive therapy, in Comprehensive textbook of
psychiatry, ed. H.I. Kaplan, B.S. Sadock, 6° vol., Baltimore, Williams and
Wilkins, 1995; 2129-40.
Duman RS, Heninger GR & Nestler EJ A molecular and cellular theory of
depression. Arch. Gen. Psychiatry 1997; 54:597-606.
Duman RS Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 2002; 17:306-10.
Duman RS, Monteggia LM A neurotrophic model for stress-related mood
disorders. Biol Psychiatry 2006; 59:1116-27.
Etgen T, Sander D, Bickel H, Förstl H.Mild cognitive impairment and
dementia: the importance of modifiable risk factors. Dtsch Arztebl Int. 2011;
108:743-50.
Fan MMY, Fernandes HB, Zhang LYJ, Hayden MR, Raymond LA. Altered
NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease. Journal of Neuroscience. 2007; 27:3768–
3779.
Fava M Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53(8):649-659.
Findeis MA. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther. 2007; 116:266–286.
Fink M, Kellner CH, Sackeim HA. Intractable seizures, status epilepticus, and
ECT. J ECT. 1999 ; 15:282-4.
Fink M. Treating bipolar affective disorder. ECT is effective. BMJ 2001 F 10; 322:365-6.
Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of
psychotic features in major depressive disorders: a review and meta-analysis. J Psychiatr Res. 2004; 38:27-35.
89
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical
method for grading the cognitive state of patients for the clinician.J Psychiatr
Res. 1975; 12:189.
Förstl H, Bickel H, Frölich L, et al. MCI-plus: leichte kognitive
Beeinträchtigung mit rascher Progredienz. Teil I: Prävention und Therapie. Dtsch Med Wochenschr. 2009; 134:39-44.
Freeman CPL, Kendell RE. ECT I: Patients' experiences and attitudes. Br J Psychiatry. 1980; 137:8–16.
Frydman-Marom A, Levin A, Farfara D, Benromano T, Scherzer -Attali R, et al. Orally administrated cinnamon extract reduces beta-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One. 2011; 6:e16564.
Galasko D, L Chang, Motter R, e coll.High cerebrospinal fluid tau and low
amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998; 55:937-945.
Geerlings MI, Schoevers RA, Beekman AT et al. Depression and risk of
cognitive decline and Alzheimer’s disease. Results of two prospective community-based studies in The Netherlands. Br J Psychiatry 2000;
176:568-75.
Geerlings MI, den Heijer T, Koudstaal PJ et al. History of depression,
depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008; 70:1258–64.
Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem. 2008; 283:29639–29643.
Gomez J. Subjective side effects of ECT. Br J Psychiatry. 1975; 127:609–11.
Gonzalo-Ruiz A, Gonzalez I, Sanz-Anquela JM Effects of b-amyloid protein
on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chemical Neuroanatomy 2003;
26: 153-169.
Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma
90
Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007; 64:354-362.
Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM Plasma beta-amyloid and white mat
ter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;
66:23-29.
Guy W ECDEU assessment manual for psychopharmacology. Rev. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch; 1976.
Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration:
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol.
2007; 8:101-112.
Hamilton M A rating scale for depression. J Neurol Neuro Neurosurg Psychiatry 1960; 23:56-62.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol.
2006; 5:228-234.
Hardy J, Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress
and problems on the road to therapeutics. Science 2002; 297:353-56.
Harvey PD, Reichenberg A, Bowie CR. Cognition and aging in
psychopathology: focus on depression and schizophrenia. Ann Rev Clin
Psychol. 2006;2:389–410.
Harvey PD Mood Symptoms, Cognition, and Everyday Functioning Innov Clin Neurosci. 2011; 8:14–18.
Hu Y, Yu X, Yang F et al. The level of serum brain-derived neurotrophic
factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT 2010;
26:121–25.
Itkin A, Dupré V, Dufrêne YF, Bechinger B, Ruysschaert JM, e Raussens V.
91
Causally Implicated in Neuronal Toxicity of Alzheimer's Disease. PLoS One.
2011;6: e18250.
Jonas BS, Brody D, Roper M, Narrow WE. Prevalence of mood disorders in a
national sample of young American adults. Soc Psychiatry Psychiatr
Epidemiol. 2003;38:618-24.
Karege F, Perret H, Bondolfi G, Schwald M, Bertschv G, Aubrey JM
Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychol Res 2002; 109: 143-148.
Karege F, Bondolfi G, Gervasoni N, Sc hwald M, Aubry JM, Bertschy G Low
Brain Derived Neurotrophic Factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57: 1068-72.
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG Common structure of soluble amyloid oligomers implies common
mechanism of pathogenesis. Science 2003; 300:486-9.
Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM.
Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry. 2008; 65:1017-32.
Kessing LV, Olsen EW, Mortensen PB, et al Dementia in affective disorder: a
case-register study. Acta Psichiatr Scand 1999; 100:176-85.
Kessing LV, Nilsson FM. Increased risk of developing dementia in patients
with major affective disorders compared to patients with other medical illnesses. J Affect Disord 2003; 73:261-9.
Kessing LV, Andersen PK Does the risk of developing dementia increase
with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004;
75:1662-66.
Kessing LV, Søndergård L, Forman JL, Andersen PK. Lithium treatment and
risk of dementia.Arch Gen Psychiatry. 2008; 65:1331-5.
92
Kieseppa T, Erp TG, Haukka J Reduced left hemispheric white matter
volume in twins with bipolar I disorder. Biol Psychiatry. 2003; 54:896–905.
Kita Y, Baba H, Maeshima H, Nakano Y, Suzuki T, Arai H Serum amyloid
beta protein in young and elderly depression: a pilot study. Psychogeriatrics
2009; 9:180-5.
Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ Amyloid-beta protein
immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11:556–561.
Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T Hippocampal
long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci U S A, 1995; 92:8856–8860.
Krishnan V, Nestler EJ The molecular neurobiology of depression. Nature 2008; 455:894–902.
Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C Mean age-of-onset of
familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 2006; 27:686–
695.
Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived
peptides as therapeutic alternatives to antibodies. Drug Discov Today. 2004;
9:525-529.
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL Diffusible, nonfibrillar ligands derived from Abeta1-42 are
potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;
95:6448-53.
Langa KM, Chernew ME, Kabeto MU, Herzog AR, Ofstedal MB, Willis RJ, Wallace RB, Mucha LM, Straus WL, Fendrick AM. National estimates of the
quantity and cost of informal caregiving for the elderly with dementia. J Gen
93
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH A specific amyloid-beta protein assembly in the brain impairs
memory. Nature 2006; 440:352-7.
Li CT, Lin CP, Chou KH, Chen IY, Hsieh JC, Wu CL, Lin WC, Su TP
Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. Neuroimage 2010;
50:347-356.
Liu R, McAllister C, Lyubchenko Y, Sierks MR. Residues 17-20 and 30-35 of
beta-amyloid play critical roles in aggregation. J Neurosci Res. 2004;
75:162-71.
Lock T, Advances in the practice of electroconvulsive therapy, "Advances in Psychiatric Treatment", 1994; 1, 47-56.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J Soluble amyloid beta peptide concentration as a
predictor of synaptic change in Alzheimer’s disease. Am J Pathol 1999;
155:853–862.
Lutch M, Kasper S Gender differences in seasonal affective disorder. Archives of Womans Menthal Health 1999; 2:83-89.
Machado-Vieira R, Dietrich MO, Leke R et al. Decreased plasma brain
derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007; 61: 142–144.
Malchiodi-Albedi F, Paradisi F, Matteucci A, Frank C, Diociaiuti M Amyloid
oligomer Neurotoxicity, calcium dysregulation, and lipid rafts Int J Alzheimers
Dis. 2011; 2011:906964.
Mannari C, Origlia N, Scatena A, Del Debbio A, Catena M, Dell'agnello G, Barraco A, Giovannini L, Dell'osso L, Domenici L, Piccinni A. BDNF level in
the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake. Cell Mol Neurobiol. 2008; 28(3):457-68.
Manji HK, Moore GJ, Chen G Lithium at 50: have the neuroprotective effects
94
Manji HK, Drevets WC & Charney DS The cellular neurobiology of
depression. Nature Med. 2001; 7:541–547.
Marano CM, Phatak P, Vemylapalli UR et al. Increased plasma concentration
of brain-derived neurotrophic factor with electroconvulsive therapy: A pilot study in patients with major depression. J Clin Psychiatry 2007; 68:512–517.
Martinez-Aran A, Torrent C, Tabares-Seisdedos R, Salamero M, Daban C, Balanza-Martinez V, Sanchez-Moreno J, Manuel Goikolea J, Benabarre A, Colom F, Vieta E. Neurocognitive impairment in bipolar patients with and
without history of psychosis. J Clin Psychiatry. 2008; 69:233-9.
Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE
Amyloid-beta peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12:376-89.
Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD. Plasma amyloid beta-peptide 1-42 and
incipient Alzheimer's disease. Ann Neurol. 1999 ;46:412-6.
McDonald C, Bullmore ET, Sham PC, Chitnis X, Wickham H, Bramon E, Murray RM Association of genetic risks for schizophrenia and bipolar
disorder with specific and generic brain structural endophenotypes. Arch Gen
Psychiatry. 2004; 61:974-984.
McLean C A, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL Soluble pool of Abeta amyloid as a determinant of
severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 1999;
46:860-66.
Merikangas KR, Kupfer DJ Mood disorders: genetic aspects. In: Kaplan HI, Sadock BJ Eds: Comprehensive Textbook of Psychiatry/IV. Baltimore, MD, William and Wilkins, 1999; 1102-16.
Miles MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, Stopa EG. Hippocampus RAGE immunoreactivity in early
and advanced Alzheimer’s disease. Brain Res 2008; 1230:273-80.
Modrego PJ, Ferrandez J Depression in patients with mild cognitive
impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004; 61:1290-93.
95
Moore PB, Shepherd DJ, Macmillan Iain C, Cerebral white matter lesions in
bipolar affective disorder: relationship to outcome. The British Journal of
Psychiatry 2001; 178: 172-176.
Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW, Drevets WC, Manji HK.A longitudinal study of the effects of lithium treatment
on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry. 2009; 70:699-705.
Moorhead TW, McKirdy J, Sussmann JE, Hall J, Lawrie SM, Johnstone EC, McIntosh AM Progressive graymatter loss in patients with bipolar disorder. Biol Psychiatry 2007; 62: 894-900.
Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, et al. Analysis of the
secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement. J Biol Chem. 2004; 279:52781-52788.
Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid
peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann
Neurol. 1995; 38:643-648.
Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD Cholinotrophic
molecular substrates of mild cognitive impairment in the elderly. Curr
Alzheimer Res 2007; 4:340-350.
Mukherjee S, Sackeim HA, Schnur DB Electroconvulsive therapy of acute
manic episodes: a review of 50 years' experience. Am J Psychiatry 1994;
151:169-176.
Nestler EJ Antidepressant treatment in the 21 st century. Biol. Psichiatry 1998; 44:526-533.
Okamoto T, Yoshimura R, Ikenouchi-Sugita A et al. Efficacy of
electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Prog Neuropsychopharmacol Biol
Psychiatry 2008; 32:1185–90.
Okereke OI, Xia W, Selkoe DJ, Grodstein F. Ten-year change in plasma
amyloid beta levels and late-life cognitive decline. Arch Neurol. 2009;
96
Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and
risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006; 63:530-8.
Palomino A, Vallejo-Illarramendi A, González-Pinto A et al. Decreased levels
of plasma BDNF in first-episode schizophrenia and bipolar disorder patients.
Schizophr Res 2006; 86: 321–322.
Pancheri P, Caredda M, L'ECT nella schizofrenia, in Trattato italiano di psichiatria, a cura di P Pancheri, GB Cassano, Milano, Masson, 1999; 1750-57.
Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER
Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 1996; 16:1137–1145.
Paykel ES Epidemiology of refractory depression. In Nolen WA, Zohar J, Roose SP, Amsterdam JD Refractory depression: current strategies and
future directions. 1994; 3-18. Wiley, New York.
Payne NA, Prudic J. Electroconvulsive Therapy Part I: A Perspective on the
Evolution and Current Practice of ECT”. J Psychiatr Pract. 2009; 15: 346–
368.
Pellistri F, Bucciantini M, Relini A, et al. Nonspecific interaction of prefibrillar
amyloid aggregates with glutamatergic receptors results in Ca2+ increase in primary neuronal cells. Journal of Biological Chemistry. 2008; 283:29950–
29960.
Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived
neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem
2005; 93:1412-21.
Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, Mount HT, Mufson EJ, Salehi A, Fahnestock M. Decreased brain-derived
neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci. 2009; 29:9321-9.
97
Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW
BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7:695–702.
Piccinni A, Marazziti D, Del Debbio A, Bianchi C, Roncaglia I, Mannari C, Origlia N, Catena Dell'Osso M, Massimetti G, Domenici L, Dell'Osso L.
Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. Chronobiol Int. 2008; 25(5):819-26.
Piccinni A, Marazziti D, Catena M et al. Plasma and serum brain-derived
neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008; 105: 279–283.
Piccinni A, Del Debbio A, Medda P, Bianchi C, Roncaglia I, Veltri A, Zanello S, Massimetti E, Origlia N, Domenici L, Marazziti D, Dell'Osso L Plasma
Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 2009;
19:349-55.
Piccinni A, Veltri A, Zanello S, Origlia N, Marazziti D, Catena Dell’Osso M, Conversano C, Moroni I, Domenici L, Dell'Osso L Plasma β-amyloid peptides
levels: a pilot study in bipolar depressed patients. Journal of affective
disorders, 2012.
Pomara N, Doraiswamy PM, Willoughby LM et al. Elevation in plasma
Abeta42 in geriatric depression: a pilot study. Neurochem Res 2006; 31:341–
49.
Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of
electroconvulsive therapy in community settings. Biol Psychiatry 2004;
55:301-312.
Qiu WQ, Sun X, Selkoe DJ et al. Depression is associated with low plasma
Abeta42 independently of cardiovascular disease in the homebound elderly.
Int J Geriatr Psychiatry 2007; 22:536-42.
Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R . Amyloid ion channels: a common structural link for
98
Regenold WT, Hisley KC, Phatak P, Marano CM, Obuchowski A, Lefkowitz DM, Sassan A, Ohri S, Phillips TL, Dosanjh N, Conley RR, Gullapalli R.
Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.
Bipolar Disord. 2008; 10:753-64.
Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, Moore PB A meta-analysis of cognitive deficits in euthymic patients with
bipolar disorder. J Affect Disord 2006; 93:105-115.
Rowan MJ, Anwyl R ,Wang Q, Beta-amyloid-mediated inhibition of NMDA
receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J
Neurosci. 2004; 24:6049-56.
Rowan MJ, Klyubin I, Wang Q, Anwyl R. Synaptic plasticity disruption by
amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Biochem Soc Trans 2005; 33:563-67.
Sackeim HA, Ross FR, Hopkins N, et al. Subjective side effects acutely
following ECT: Associations with treatment modality and clinical response.
Convuls Ther.1987; 3:100-10.
Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive
symptoms and risk of dementia: the Framingham Heart Study. Neurology.
2010; 75:35-41.
Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, Suemoto T, Higuchi M, Saido TC Somatostatin regulates brain amyloid beta peptide
Abeta42 through modulation of proteolytic degradation. Nat Med 2005;
11:434-439.
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W et al. Secreted amyloid beta-protein similar to
that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease.
Nat Med 1996; 2:864-870.
Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer's
99
Selkoe DJ, Schenk D Alzheimer's disease: molecular understanding predicts
amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43: 545-84.
Selkoe DJ The ups and downs of Abeta. Nat Med 2006; 12:758-759.
Sen S, Duman R, Sanacora G Serum brain-derived neurotrophic factor,
depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 2008; 64:527–32.
Seppälä TT, Herukka SK, Hänninen T, Tervo S, Hallikainen M, Soininen H, Pirttilä T. Plasma Abeta42 and Abeta40 as markers of cognitive change in
follow-up: a prospective, longitudinal, population-based cohort study. J
Neurol Neurosurg Psychiatry. 2010; 81:1123-7.
Seubert P , Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al Secretion of beta-amyloid precursor
protein cleaved at the amino terminus of the beta-amyloid peptide. Nature.
1993; 361:260-3.
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL Natural oligomers of the Alzheimer amyloid-beta protein induce reversible
synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27:2866 –2875.
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ Soluble amyloid-beta protein dimers isolated directly
from Alzheimer disease patients potently impair synaptic plasticity and memory. Nat Med 2008; 14:837–842.
Sheehan DV, Lecrubier Y et al. Mini International Neuropsychiatric Interview
(M.I.N.I.). University of South Florida Institute for Research in Psychiatry,
Tampa, Florida and INSERM - Hopital de la Salpétrière, Paris, France, 1994.
Sheline YI, Wang PV, Gado MH, Csernansky JG, Vannier M W Hippocampal
atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996; 93:
3908-3913.
Sheline YI, Gado MH, Kraemer HC.Untreated depression and hippocampal
100
Shi Y, You J, Yuan Y, Zhang X Plasma BDNF and tPA are associated with
late-onset geriatric depression. Psychiatry Clin Neurosci 2010; 64: 239–248.
Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV Clearance of
Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106:1489–99.
Siegel GJ, Chauhan NB Neurotrophic factors in Alzheimer's and Parkinson's
disease brain. Brain Res Brain Res Rev 2000; 33:199-227.
Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J. Ultra-brief pulse
ECT in bipolar and unipolar depressive disorder: differences inspeed of response. Bipolar Disord 2009: 11: 418-424.
Simonsen C, Sundet K, Vaskinn A et al. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord2008; 10: 245-255.
Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P Regulation of NMDA
receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8:1051-1058.
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J Treatment resistant depression:
methodological overview and operational criteria. Eur
Neuropsychopharmacol 1999; 9:83-91.
Strakowski SM, Delbello MP, Adler CM The functional neuroanatomy of
bipolar disorder: a review of neuroimaging findings. Mol. Psychiatry 2005;
10:105–116.
Sulser F, Vetulani J & Mobley PL Mode of action of antidepressant drugs. Biochem. Pharmacol. 1978; 27:257-261.
Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ. Amyloid-associated depression: a prodromal
depression of Alzheimer disease? Arch Gen Psychiatry 2008; 65:542-50.
Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the
101
cognitive decline in Alzheimer disease. Journal of Neuropathology and
Experimental Neurology 1997; 56:933–944.
Tardito D, Perez J, Tiraboschi E, Musazi L, Racagni G, Popoli M Signaling
pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview Pharmacol
Rev 2006; 58:115-134.
Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R, Hansen LA, Katzman R Physical basis of cognitive alterations in Alzheimer's disese:
synapse loss is the major correlate of cognitive impairment . Ann Neurol
1991; 30:572-80.
Thase ME and Rush AJ When at first you don't succeed: sequential
strategies for AD nonresponders. J Clin Psychiatry 1997; 58(13):23-29.
Tohen M, Zarate CA Jr, Hennen J, . Khalsa HM, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ. The McLean-Harvard First-Episode
Mania Study: prediction of recovery and first recurrence. Am J Psychiatry
2003; 160:2099–2107.
Tong L, Thornton PL, Balazs R, Cotman CW Beta-amyloid-(1–42) impairs
activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol
Chem 2001; 276:17301–17306.
Torrent C, Martínez-Arán A, Daban C, Sánchez-Moreno J, Comes M, Goikolea JM, Salamero M, Vieta E Cognitive impairment in bipolar II disorde. Br J Psychiatry 2006; 189:569.
Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in
euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand. 2007;
434:17–26.
Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ Effects of
secreted oligomers of amyloid-beta protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572:477–492.
Trivedi MH, Rush JA Winiewski SR Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B e coll. Evaluation of outcomes with
102
citalopram for depression using easurament-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163(1):28-40.
Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global
burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;
184:386-92.
van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and
white matter lesions. Ann Neurol 2004; 55:570-575.
Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma
Aβ1–40 and Aβ1–40 and the risk of dementia: a prospective case-cohort study.
Lancet Neurol. 2006; 5:655-660.
Visser PJ, Verhey FR, Ponds RW, Kester A, Jolles J Distinction between
preclinical Alzheimer's disease and depression. J Am Geriatr Soc 2000;
48:479-84.
Waddington JL, Brown K, O'Neill J, McKeon P, Kinsella A Cognitive
impairment, clinical course and treatment history in out-patients with bipolar affective disorder: relationship to tardive dyskinesia. Psychol Med.
1989;19:897-902.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ Naturally secreted oligomers of amyloid beta protein potently
inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-539.
Walsh DM, Selkoe DJ. Oligomers in the brain: the emerging role of soluble
protein aggregates in neurodegeneration. Protein and Peptide Letters. 2004;
11:213-228.
Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ The role of
cell-derived oligomers of Abeta in Alzheimer’s disease and avenues for therapeutic intervention. Biochem Soc Trans 2005; 33:1087-90.
Weissman MM, Bland RC, Canino GJ et al Cross-national epidemiology of
major depression and bipolar disorder. JAMA 1996; 276:293-99.
Weissman MM, Klerman GL Sex differences and the epidemiology of
103
Wilson RS, Barnes LL, Mendes de Leon CF et al. Depressive symptoms,
cognitive decline, and risk of AD in older persons. Neurology 2002;
59:364-70.
Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment–beyond
controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004; 256:240-246.
Wong ML, Kling MA, Munson PJ et al Pronounced and sustained central
hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl
Acad Sci USA 2000; 97:325-30.
Wong ML & Licinio J From monoamines to genomic targets: a paradigm shift
for drug discovery in depression. Nature Rev. Drug Disc. 2004; 3:136-150.
Xu Y-L, Reinscheid RK, Hitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O
Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects.
Neuron 2004; 43:487-497.
Yaffe K, Weston A, Graff-Radford NR, Satterfield S , Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB.Association of
plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011; 305:261-6.
Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE
and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996;
382:685-91.
Young AH, Macritchie KAN, Calabrese JR. Treatment of bipolar affective
disorder. BMJ. 2000; 321:1302-1303.
Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I. Full length
mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington’s disease.
Neurobiology of Disease. 2008; 31:80-88.
Zhang YW, Thompson R, Zhang H, Xu H APP processing in Alzheimer's
104
Zheng H, Koo EH The amyloid precursor protein: beyond amyloid. Mol Neurodegener. 2006; 1:5.
